NextCure (NXTC) Insider Elaine Jones Buys 2,340 Shares

Elaine Jones Buys NextCure, Inc. NXTC Shares

Elaine Jones added to her stake in NextCure, Inc. NXTC by purchasing 2,340 shares on June 18, 2026. This purchase did not happen in isolation, forming part of a broader round of insider acquisitions at the clinical-stage biopharmaceutical firm on that exact date.

Insider Buying and Selling at NextCure, Inc.

Jones was joined by several colleagues who also stepped up to buy shares on June 18, 2026. David Kabakoff purchased 3,510 shares of NextCure, Inc. NXTC on the same day. Stephen Webster also bought 2,340 shares, while John Houston picked up 2,340 shares. In addition, Borgman Anne Elizabeth purchased 2,340 shares of NextCure, Inc. NXTC on June 18, 2026, rounding out a busy day of insider transactions for the company.

NextCure, Inc. NXTC Stock Price Context

The transactions took place as NextCure, Inc. NXTC changed hands at a spot price of $1.75 on Tuesday. The shares trade far below their 52-week high of $15.74 and sit near the bottom of their 52-week range, which bottoms out at $1.55. The company carries a market capitalization of roughly $25.0 million.

What NextCure, Inc. NXTC Does

NextCure, Inc. NXTC operates as a clinical-stage biopharmaceutical company focused on discovering and advancing targeted medicines for cancer and other serious conditions. Headquartered in Baltimore, Maryland, the firm works on antibody-drug conjugates and novel protein therapies designed to address unmet medical needs in oncology and immunology.

Looking Ahead for NextCure, Inc. NXTC

Investors will likely watch for subsequent regulatory updates and future Form 4 filings to see how insider ownership evolves. The company's next earnings report is anticipated around July 30, 2025.